FDA approves Lucentis for vision loss-related disease
SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has approved a drug made by Genentech for treating a disease of the eye, the Roche subsidiary said Tuesday.
The FDA approved Lucentis (ranibizumab) for macular edema following retinal vein occlusion. RVO affects more than 1 million people in the United States, usually those older than 50, and is a common cause of vision loss. The FDA approved Lucentis in 2006 as a treatment for neovascular age-related macular degeneration, another common cause of vision loss.
“This approval provides an important new medicine for people experiencing the unexpected vision loss associated with macular edema following RVO,” Genentech EVP global development and chief medical officer Hal Barron said. “In the Lucentis RVO clinical trials, significantly more people treated with monthly Lucentis showed sustained vision improvement during the six-month study with an effect seen as early as seven days.”
New line of cards from American Greetings now feature iTunes download
CLEVELAND There’s something new and musical in the greeting card aisle.
American Greetings has introduced greeting cards that feature a song download from iTunes, the company announced Tuesday. The complete line includes 36 cards, each with a code redeemable for a song download from iTunes. There also are eight gift card holders that can be used to send any iTunes gift card.
“From our research, we already knew that consumers loved the pairing of music and greeting cards, and we wanted to elevate the overall experience,” said Carol Miller, executive director of new product concepts at American Greetings. “By giving someone a card with a gift that empowers them to choose their own song, you make the connection even more personal and enjoyable, which is what sending a card is all about.”
Targus develops screen protector for Apple iPad
NEW YORK A maker of computer cases and accessories unveiled its latest innovation — a screen protector for the Apple iPad.
Targus’ new screen protector is designed to reduce fingerprints and smudges. With the added features of anti-glare treatment and specially formulated adhesive that prevents bubbles and peeling, it is the most comprehensive screen protector for your iPad available on the market, Targus said.
“Using microstructures in a film to resist fingerprints can trap oils and paper fibers over time causing the screen to appear cloudy,” stated Carolyn Perrier, VP accessories product management and marketing at Targus. “The improved Targus screen potector is engineered to not only resist fingerprints and scratches, but also the oils and fibers that can compromise clarity. This feature along with the anti-glare treatment and bubble free, easy to apply adhesive offers the most comprehensive screen protection available for the iPad on the market today.”
Targus screen protector for the Apple iPad is priced at an MSRP of $29.99.